Cagrilintide Combined with Semaglutide: A New Approach for Treatment of Obesity and Type 2 Diabetes ClinicSearch Once weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double blind, placebo controlled and active controlled, dose finding phase 2 trial The Lancet Good looking results for Novo Nordisk's combo of GLP1ra semaglutide (known as #ozempic for #diabetes & #wegovy for obesity) + Cagrilintide (amylin agonist) to achieve #weightloss in obesity and obesity with type Clinical trials of subcutaneous tirzepatide (SURMOUNT 1, 2 and 3 Download Scientific Diagram Efficacy and safety of co administered once weekly cagrilintide 24 mg with once weekly semaglutide 24 mg in type 2 diabetes: a multicentre, randomised, double blind, active controlled, phase 2 trial The Lancet